Login
http://www.aldaorg.net
Error
  • JUser: :_load: Unable to load user with ID: 44
Category: Accreditation
Print
Indonesia offers a growing market for oncology products with cancer being the sixth most leading cause of death in that country

  Chandigarh  February 6, 2014 : - Drug major  today said it has got good manufacturing practices () certification from Indonesia for its unit located at Baddi in Himachal Pradesh.
    
Indonesian National Agency for Drug and Food Control (NADFC) granted the certification after an extensive review and audit of the facility, said a company statement issued here today.
    
"Such recognitions for our manufacturing facilities and consistent quality of our procedures and practices open tremendous opportunities for us to expand our product portfolio across the globe... This GMP approval will soon pave the way for marketing authorisations from Indonesia," said Manu Chaudhary, Joint Managing Director, Venus Remedies Ltd.
    
Indonesia offers a growing market for  products with cancer being the sixth most leading cause of death in that country after infectious diseases, cardiovascular diseases, traffic accidents, nutritional deficiency and congenital diseases.
    
With a sizable population of 234 million, with a rapidly expanding middle class, Indonesia is poised to emerge as a key market of growth for the healthcare and pharmaceutical industry.
    
Currently worth $4.5 billion, Indonesia's pharmaceutical market is expanding at an annual rate of 12.5 per cent.
    
"A potential market for our oncology product line, Indonesia records 170-190 new cancer cases annually in a population of every 1 lakh. The Indonesian oncology market, worth $88.58 million in 2013, is expected to grow at 10 per cent.
    
"We will commercially launch our products in Indonesia by the middle of this year and are projected to generate revenue of $1 million in the first year itself. With the launch of our oncology products in Indonesia, we aim at capturing the maximum share in the country's pharmaceutical market," said company's CFO, Dheeraj Aggarwal.
    
The pharma major has three manufacturing units - in Panchkula (Haryana), Baddi (HP) and Werne (Germany). It also has 11 overseas marketing offices, including a presence in the US and Germany.- Business standard  
 
Category: Accreditation
Print
                            
Lupin shares gains more than 1% on US health regulator’s nod for generic Trizivir tablets

New Delhi December 11, 2013:  
Drug major Lupin Ltd on Tuesday said it has received US health regulator’s approval to market generic version of ViiV Healthcare Ltd’s Trizivir tablets, used in the treatment of HIV-1 infection, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) for its Abacavir Sulfate Lamivudine, and Zidovudine tablets, Lupin said in a statement.
 
The company’s product is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection, it added.
“Lupin was the first applicant to file an abbreviated new drug application (ANDA) for Trizivir tablets and as such will be entitled to 180 days of marketing exclusivity,” the company said.
 
According to IMS MAT September 2013 sales data, Trizivir tablets has US sales of around $111.6 million.
Lupin’s cumulative ANDA filings with the USFDA as of 30 October stands at 183 and the Mumbai-headquartered firm has received 93 approvals to date.
 
During the current year, the company has so far received 17 approvals from USFDA. It has also launched 13 products in the US market in the current year so far.

“Lupin is the market leader in 26 products in the US generic market and is amongst the top three by market share in 40 products out of the overall 57 products in the market,” it the company said.
 
Shares of Lupin were trading at Rs.863.70 a piece on the BSE in afternoon trade, up 1.28% from its previous close.
 
Category: Accreditation
Print

New Delhi, June 28 2013: The Cabinet Committee on Economic Affairs today approved the continuation of the National Mission on Food Processing (NMFP) for the remainder of 12th Five Year Plan (2013-17) based on detailed proposals submitted by the Ministry of Food Processing Industries (MOFPI). 


The NMFP outlay for 2012-17 has been kept at Rs. 1,600 crore consisting of Rs. 1,250 crore provided by the Government of India (GOI) and corresponding State share of Rs. 350 crore. This includes Rs. 320 crore already approved for 2012-13, of which Rs. 250 crore was the GOI share and Rs. 70 crore was the State share. 

The following schemes under the NMFP will be implemented by State Governments for the remainder of 12th Five Year Plan in pursuance of today's approval: 

i. Scheme for technology up-gradation / establishment / modernisation of food processing industries. 

Read more...
 
Category: Accreditation
Print

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Ondansetron Injection USP 2rng/mL packaged in 40mg/20mL Multiple-dose Vials (ANDA 202599) and Ondansetron Injection USP 2mg/mL packaged in 4mg/2mL Single-dose Vials, Preservative-free (ANDA 202600). The products are ready for launch.

Read more...
 
Email address:


Prev Next
Lenskart
MedLife
HealthKart
"ACCURA" MODEL ACT -III High Speed Double Rotary Tablet Presses
Pharmaceutical Labeling Equipment
The Power Times.in
The SME Times
 The Pharma Times News Portal
The Hotel Times
  • 1
  • 2
Prev Next
Omron Blood Pressure Monitor, HEM-7113
Automatic Capsule Filling Machine (PF-150)
Gelusil liquid antacid - Pfizer’s
The Varilux 3.0 range lenses - Essilor
Blossom Kochhar Aroma Magic Anti Pigmentation Serum
 The Property Times